Clinical Trials

692 enrolled 11 charts

Phase 2/3 Active not recruiting

Brenner Tumor, Fallopian Tube Neoplasms

NCT02839707 2026-04-13

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

444 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03694262 2026-04-13

EndoBARR

30 enrolled 7 charts

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

72 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 2 FDA

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT02734004 2026-01-29

MEDIOLA

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT02364713 2025-12-11

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

17 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01081262 2025-11-25

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

50 enrolled 13 charts

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02142803 2025-11-13

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

50 enrolled 16 charts

CNSGynecologic

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT00977574 2025-10-31

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT03740165 2025-10-22

KEYLYNK-001

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05446870 2025-10-01

MK-4830-002

160 enrolled 19 charts

Ovarian Neoplasms

NCT03326193 2025-07-31

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

105 enrolled 29 charts

Ovarian Neoplasms

NCT03574779 2025-07-15

OPAL

77 enrolled 8 charts

Ovarian Neoplasms

NCT00513786 2025-03-28

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

38 enrolled 12 charts

Endometrial Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03635489 2024-10-03

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

100 enrolled 22 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03367871 2024-06-18

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

17 enrolled 12 charts

Uterine Cervical Neoplasms

NCT02606305 2024-06-14

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1/2 Completed

264 enrolled 41 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03093155 2024-05-14

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

78 enrolled 18 charts

GastrointestinalGynecologicThoracic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03250832 2024-04-11

CITRINO

Phase 1 Completed

111 enrolled 48 charts

Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02923739 2024-03-13

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

9 enrolled 9 charts

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04551950 2024-03-08

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

Phase 1 Completed

25 enrolled 14 charts

Uterine Cervical Neoplasms, Camurati-Engelmann Syndrome

NCT03476798 2024-02-15

Clovis-001

49 enrolled 13 charts

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT05751629 2023-04-21

COHORT-A

41 enrolled 17 charts

Ovarian Neoplasms

NCT02921269 2023-02-21

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

11 enrolled 11 charts

Uterine Cervical Neoplasms

NCT03038100 2023-02-17

IMagyn050

1,301 enrolled 22 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04753216 2023-01-19

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

3 enrolled 15 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01097746 2022-10-28

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

33 enrolled 10 charts

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00976911 2022-06-21

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

361 enrolled 15 charts

Ovarian Neoplasms

NCT00886691 2022-02-04

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

150 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01551745 2021-10-19

Salvage Ovarian FANG™ Vaccine + Bevacizumab

5 enrolled 9 charts

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02853318 2021-10-06

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

40 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03394885 2021-08-12

AdORN

Phase 1/2 Completed

18 enrolled 15 charts

Ovarian Neoplasms

NCT01146795 2021-02-09

Neoadjuvant Therapy for Ovarian Cancer

32 enrolled 10 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00436215 2020-11-23

Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer

55 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02661815 2019-11-08

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

Phase 1 Terminated

6 enrolled 8 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01305213 2019-07-30

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

107 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00022659 2019-07-24

Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

64 enrolled 11 charts

Carcinoma, Ovarian Epithelial

NCT00025233 2019-07-24

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

50 enrolled 15 charts

Uterine Cervical Neoplasms

NCT00301964 2019-07-24

Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

56 enrolled 13 charts

Endometrial Neoplasms

NCT00262847 2019-07-23

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

1,873 enrolled 17 charts 2 FDA

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00723255 2019-07-23

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

53 enrolled 15 charts

Endometrial Neoplasms

NCT00748657 2019-07-23

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

36 enrolled 7 charts

Granulosa cell tumor of the ovary, Ovarian gynandroblastoma, Sertoli-Leydig Cell Tumor

NCT00803062 2019-07-23

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

452 enrolled 11 charts

Uterine Cervical Neoplasms

NCT02664961 2019-07-23

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

3 enrolled 11 charts

Choriocarcinoma, Trophoblastic Tumor, Placental Site, Gestational Trophoblastic Disease

NCT01010126 2019-01-25

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

GastrointestinalGynecologic

252 enrolled 20 charts

Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Somatostatinoma

NCT00856180 2018-09-10

Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies

20 enrolled 9 charts